Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2018 08:30 ET | Source: Avinger, Inc.

Avinger Announces Presentations and Posters Featuring Lumivascular Technology at New Cardiovascular Horizons Annual Conference

REDWOOD CITY, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of...
May 29, 2018 08:30 ET | Source: Avinger, Inc.

Avinger to Present at the 8th Annual LD Micro Invitational

REDWOOD CITY, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that it will be...
May 23, 2018 08:30 ET | Source: Avinger, Inc.

Avinger Receives FDA Clearance of Next Generation Pantheris Device

REDWOOD CITY, Calif., May 23, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company...
May 14, 2018 16:15 ET | Source: Avinger, Inc.

Avinger Announces First Quarter 2018 Financial Results

REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the...
May 04, 2018 08:00 ET | Source: Avinger, Inc.

Avinger to Announce First Quarter 2018 Financial Results on May 14, 2018

REDWOOD CITY, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will...
April 30, 2018 08:30 ET | Source: Avinger, Inc.

Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Charing Cross International Symposium 2018

REDWOOD CITY, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that its next...
March 29, 2018 09:00 ET | Source: Avinger, Inc.

Avinger Announces First-in-Patient use of Extended Nosecone Version of Next Generation Pantheris

REDWOOD CITY, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Arne...
March 21, 2018 08:00 ET | Source: Avinger, Inc.

Avinger Enters into Settlement Agreement for All Outstanding Securities Class Action Litigation

REDWOOD CITY, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD),...
March 19, 2018 16:01 ET | Source: Avinger, Inc.

Avinger Announces Fourth Quarter and Full Year 2017 Results

REDWOOD CITY, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD),...
March 13, 2018 08:00 ET | Source: Avinger, Inc.

Avinger Provides Update on U.S. Intellectual Property Portfolio

REDWOOD CITY, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced three recent...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right